Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy.
The digestive vacuole plasmepsins PfPM1, PfPM2, PfPM4, and PfHAP (a histoaspartic proteinase) are 4 aspartic proteinases among 10 encoded in the Plasmodium falciparum malarial genome. These have been hypothesized to initiate and contribute significantly to hemoglobin degradation, a catabolic function essential to the survival of this intraerythrocytic parasite. Because of their perceived significance, these plasmepsins have been proposed as potential targets for antimalarial drug development. To test their essentiality, knockout constructs were prepared for each corresponding gene such that homologous recombination would result in two partial, nonfunctional gene copies. Disruption of each gene was achieved, as confirmed by PCR, Southern, and Northern blot analyses. Western and two-dimensional gel analyses revealed the absence of mature or even truncated plasmepsins corresponding to the disrupted gene. Reduced growth rates were observed with PfPM1 and PfPM4 knockouts, indicating that although these plasmepsins are not essential, they are important for parasite development. Abnormal mitochondrial morphology also appeared to accompany loss of PfPM2, and an abundant accumulation of electron-dense vesicles in the digestive vacuole was observed upon disruption of PfPM4; however, those phenotypes only manifested in about a third of the disrupted cells. The ability to compensate for loss of individual plasmepsin function may be explained by close similarity in the structure and active site of these four vacuolar enzymes. Our data imply that drug discovery efforts focused on vacuolar plasmepsins must incorporate measures to develop compounds that can inhibit two or more of this enzyme family.
Omara-Opyene
A Levi
AL
Department of Pathobiology, University of Florida, Gainesville, Florida 32611-0880, USA.
Moura
Pedro A
PA
Sulsona
Carlos R
CR
Bonilla
J Alfredo
JA
Yowell
Charles A
CA
Fujioka
Hisashi
H
Fidock
David A
DA
Dame
John B
JB
D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000235:genetics* / Q000502:physiology*; D015152:Blotting, Northern; D015139:Blotting, Southern; D015153:Blotting, Western; D003001:Cloning, Molecular; D015180:Electrophoresis, Gel, Two-Dimensional; D004791:Enzyme Inhibitors; D004912:Erythrocytes / Q000469:parasitology; D005818:Genetic Engineering; D006454:Hemoglobins / Q000378:metabolism; D008854:Microscopy, Electron; D010963:Plasmodium falciparum / Q000201:enzymology / Q000235:genetics* / Q000254:growth & development; D014162:Transfection; D014617:Vacuoles / Q000201:enzymology
D004791:Enzyme Inhibitors; D006454:Hemoglobins; D016282:Aspartic Acid Endopeptidases; C089643:plasmepsin